Fintech PR
Commercial Insurance Market Soars at 8.4% CAGR, Reaching US$2.1 Trillion by 2034, Fueled by Demand for Advanced Coverage | Future Market Insights, Inc.
Sophisticated scams, SME competition, diverse insurance providers, stable premiums, and AI-driven efficiencies key drivers of commercial insurance market growth. Learn more & unlock stakeholder opportunities in our full report
NEWARK, Del., Jan. 10, 2024 /PRNewswire/ — The Global Commercial Insurance Market value is expected to rise from US$ 935 million in 2024 to US$ 2,094.70 million by 2034. This estimated growth is expected to be driven by a promising CAGR of 8.40% in the commercial insurance market over the next decade.
Request Exclusive Sample Report: Commercial Insurance Market Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-18734
Enterprises are increasingly opting for insurance policies to protect their business from sophisticated scams. Further, rising competitiveness among small and medium-sized businesses, along with increasing commercial insurance providers infiltrating the marketplace, is projected to expand the market.
The presence of a significant count of commercial insurance providers is also uplifting the market conditions due to the availability of insurance policies for all business sizes and types. Moreover, many business owners are adopting commercial insurance based on premiums charged for the policies, as the premiums stay the same throughout the market. Thus accelerating the market growth over the forecast period.
Industry veterans think highly of artificial intelligence, which is being utilized in commercial insurance. Currently, they expect that artificial intelligence is going to aid insurance professionals with potent tools necessary to bring efficiencies. Thus helping the market advance further.
“Key players are projected to target high-growth segments in the industry. On that score, large enterprise size and liability insurance are on top of their mind, and players are customizing their solutions accordingly. Industry participants are also expected to integrate AI and ML in their operations to streamline their operations and bring efficiencies,” says Sneha Varghese (Senior Consultant, Consumer Products & Goods) has 6+ years of experience in the market research and consulting industry.
Key Takeaways from the Commercial Insurance Market Report
- The market expanded at a CAGR of 7.80% from 2019 to 2023. Meanwhile, from 2024 to 2034, the market is projected to expand at a CAGR of 8.40%.
- The United States liability insurance market is predicted to record a CAGR of 8.20% through 2034.
- Within Europe, the German liability insurance market is forecast to expand at a CAGR of 8.60% through 2034.
- The market in China is forecast to register a CAGR of 8.70%, whereas the market in India is projected to register a CAGR of 8.90% through 2034.
- The Australia liability insurance market is projected to record a CAGR of 9.20% through 2034.
- By type, the liability insurance is projected to acquire a share of 14.5% in 2024.
- Based on enterprise size, the large segment is anticipated to obtain a share of 47.90% in 2024.
Industry Players Strategizing for a Larger Pie of the Market
Key players are employing several strategies to up their game in the market. These tactics include expansion of product offerings, collaborations, mergers and acquisitions, agreements, and geographical expansion.
Leading Players in Commercial Insurance Industry:
- Allianz SE
- American International Group Inc.
- Aon plc
- Aviva plc
- Axa S.A.
- Chubb Limited
- Direct Line Insurance Group plc
- Marsh & McLennan Companies Inc.
- Willis Towers Watson Public Limited Company
- Zurich Insurance Group Ltd.
- Others
Purchase this report now to get key companies with their Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis.
New Developments Shaping the Commercial Insurance Market
- American International Group Inc. (AIG), in April 2023, completed an agreement with Stone Point. The agreement includes the launch of the Managing General Agency (MG), which has a high net worth. This partnership is projected to optimize the strengths of this business and enhance product offerings to effectively serve High as well as Ultra High Net Worth markets.
- In July 2023, Allianz is projected to cater to the commercial insurance segment as a default market business. Distribution partners and clients are expected to benefit from a more steady trading approach and comprehensive solutions under a single model.
About the Author:
Sneha Varghese (Senior Consultant, Consumer Products & Goods) has 6+ years of experience in the market research and consulting industry. She has worked on 200+ research assignments pertaining to Consumer Retail Goods.
Her work is primarily focused on facilitating strategic decisions, planning and managing cross-functional business operations, technology projects, and driving successful implementations. She has helped create insightful, relevant analysis of Food & Beverage market reports and studies that include consumer market, retail, and manufacturer research perspective. She has also been involved in several bulletins in food magazines and journals.
Explore FMI’s Extensive Coverage in the Consumer Products and Retail Domain
- Liquid Carton Packaging Market By Type, Application & Region – Forecast 2022 – 2032. – Review and Request to Access the PDF Sample Study.
- Demand and Trend Analysis of Cosmetics ODM in Korea, Forecast 2024 to 2034. – Review and Request to Access the PDF Sample Study.
- Demand and Trend Analysis of Cosmetics ODM in Japan, Forecast 2024 – 2034. – Review and Request to Access the PDF Sample Study.
- Demand and Trend Analysis of Cosmetics ODM in Western Europe, Forecast 2024 – 2034. – Review and Request to Access the PDF Sample Study.
- Premium Bicycle Market Forecast by Electronic and Conventional Technology from 2024 to 2034. – Review and Request to Access the PDF Sample Study.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the United Kingdom, the United States, and India. FMI’s latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition.
Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg
View original content:
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
Money20/20 Asia 2024: Days Two Roundup
-
Latest News3 days ago
Letter from Gatemore Capital Management LLP to Elementis PLC
-
Latest News4 days ago
Shanghai Electric Releases ESG Report, Highlighting Sustainable Development Achievements in 2023
-
Latest News6 days ago
Stripe Unveils Unbundled Payments Strategy in Fintech Pivot
-
Latest News3 days ago
Hyosung Heavy Industries Ranked on BNEF’s Energy Storage Tier 1 List
-
Latest News6 days ago
Former Tesla executive Tim Newell is set to spin off Aspiration’s consumer financial services division.
-
Latest News7 days ago
Payflows Emerges from Stealth with €25 Million Series A Funding Round
-
Latest News6 days ago
Zafin Unveils Strategic Leadership Transition in Canadian SaaS Fintech